Check for updates

OPEN ACCESS

EDITED BY Ping Zhang, The Ohio State University, United States

REVIEWED BY Gowthami Sai Kogilathota Jagirdhar, Saint Michael's Medical Center, United States Pranjal Sharma, Northeast Ohio Medical University, United States

*CORRESPONDENCE Lu-Huai Feng 23900187@qq.com

[†]These authors have contributed equally to this work and share first authorship

RECEIVED 01 August 2024 ACCEPTED 23 September 2024 PUBLISHED 03 October 2024

CITATION

Wei C, Cao H, Huang L and Feng L-H (2024) Development and validation of a web-based nomogram for acute kidney injury in acute non-variceal upper gastrointestinal bleeding patients. *Front. Med.* 11:1474311.

doi: 10.3389/fmed.2024.1474311

COPYRIGHT

© 2024 Wei, Cao, Huang and Feng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Development and validation of a web-based nomogram for acute kidney injury in acute non-variceal upper gastrointestinal bleeding patients

Chaolian Wei^{1†}, Honghua Cao^{2†}, Lina Huang³ and Lu-Huai Feng³*

¹Department of Gastric and Abdominal Tumor Surgery, Guangxi Medical University Cancer Hospital, Nanning, China, ²Department of Gastrointestinal Surgery, Guigang People's Hospital, Guigang, China, ³Department of Endocrinology and Metabolism Nephrology, Guangxi Medical University Cancer Hospital, Nanning, China

Background: Acute kidney injury (AKI) is a common and serious complication in patients with acute non-variceal upper gastrointestinal bleeding (NVUGIB). Early prediction and intervention are crucial for improving patient outcomes.

Methods: Data for patients presenting with acute NVUGIB in this retrospective study were sourced from the MIMC-IV database. Patients were randomly allocated into training and validation cohorts for further analysis. Independent predictors for AKI were identified using least absolute shrinkage and selection operator regression and multivariable logistic regression analyses in the training cohort. Based on the logistic regression results, a nomogram was developed to predict early AKI onset in acute NVUGIB patients, and implemented as a web-based calculator for clinical application. The nomogram's performance was evaluated through discrimination, using the C-index, calibration curves, and decision curve analysis (DCA) to assess its clinical value.

Results: The study involved 1082 acute NVUGIB patients, with 406 developing AKI. A multivariable logistic regression identified five key AKI predictors: CKD, use of human albumin, chronic liver disease, glucose, and blood urea nitrogen. The nomogram was constructed based on independent predictors. The nomogram exhibited robust accuracy, evidenced by a C-index of 0.73 in the training cohort and 0.72 in the validation cohort. Calibration curves demonstrated satisfactory concordance between predicted and observed AKI occurrences. DCA revealed that the nomogram offered considerable clinical benefit within a threshold probability range of 7% to 54%.

Conclusion: Our nomogram is a valuable tool for predicting AKI risk in patients with acute NVUGIB, offering potential for early intervention and improved clinical outcomes.

KEYWORDS

acute kidney injury, prediction, nomogram, intensive care unit, upper gastrointestinal bleeding

Introduction

Acute non-variceal upper gastrointestinal bleeding (NVUGIB) is a common and serious condition frequently observed in intensive care units (ICU), resulting in substantial morbidity and mortality rates. The in-hospital mortality rate following acute NVUGIB typically ranges from 5% to 15%, but may escalate to 35% among elderly patients with acute kidney injury (AKI) (1). Approximately 5% of hospitalized patients suffer an AKI, with an incidence of 30 - 57% in intensive care units (2), with the average pooled mortality rate of 23% but reached 49.4% in those requiring g kidney replacement therapy (3, 4). Existing literature indicates that AKI occurs in 1-11.4% of patients with acute NVUGIB, and those with acute NVUGIB complicated by AKI have longer hospital stays and higher mortality rates (1, 5). Therefore, early identification of high-risk patients is critical for the prevention of AKI, and early diagnosis and treatment can improve the long-term prognosis of patients (6).

The current diagnostic criteria for AKI as outlined by the Kidney Disease Improving Global Outcomes (KDIGO), an increase in serum creatinine or a decline in urine output remains its key diagnostic criteria (7). However, current clinical detection methods, which rely on creatinine levels and urine output, are inadequate for early AKI diagnosis, AKI is rarely diagnosed and mild cases are often missed (8, 9). In recent years, significant progress has been made in the early diagnosis of AKI due to advancements in information technology, nanotechnology, and biomedicine. Although certain studies have proposed alternative biomarkers-such as cystatin C, neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, and liver-type fatty acid binding protein-for the early detection of kidney damage preceding serum creatinine elevation (4), the diagnostic accuracy of these biomarkers remains limited (4, 10, 11). Consequently, further research is imperative to develop tools capable of predicting AKI at an early stage.

Machine learning, a subset of artificial intelligence, has demonstrated efficacy in predicting AKI through the development of predictive models that analyze extensive datasets pertaining to medical treatments and outcomes. The nomogram, a widely utilized visualization technique in machine learning, serves as a dependable instrument for predicting and quantifying the risk of clinical events (12, 13). While risk prediction models for AKI in cirrhotic patients with gastric variceal bleeding are relatively well-established (14, 15), there remains a notable deficiency in risk prediction models for AKI in patients experiencing upper gastrointestinal bleeding due to acute non-variceal causes. Our study identified a combination of routinely available clinical variables that could be used for the highly precise prediction of acute NVUGIB with AKI in critically ill patients.

Materials and methods

The methodologies described in this article are consistent with the guidelines established in the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) statement (16).

Ethics approval and consent to participate

The establishment of MIMIC-IV (version 2.2) was approved by the institutional review boards of the Beth Israel Deaconess Medical Center (Boston, MA) and Massachusetts Institute of Technology (Cambridge, MA), thus, this study was granted a waiver of informed consent.

Database

The study utilized data from the publicly available MIMIC-IV database (version 2.2), a robust critical care database situated in the United States. This database encompasses clinical information from a vast cohort of over 190,000 patients and 450,000 hospitalizations spanning the years 2008 to 2019. The data captured within the database includes a comprehensive array of patient demographics, laboratory tests, medications, vital signs, disease diagnoses, drug management, and follow-up survival outcomes.

Participants

The study's criteria for inclusion consisted of adult patients aged 18 years and older who were admitted to the ICU with acute NVUGIB. Exclusion criteria encompassed individuals with a baseline creatinine level suggestive of stage 5 chronic kidney disease (CKD) or those undergoing frequent renal replacement therapy.

Patients were assigned to groups utilizing a pre-seeded random number generator (123) in R software version 4.3.3, and subsequently divided into training and validation sets at a ratio of 7:3.

Data extraction

Data was extracted from the MIMIC-IV database using PostgreSQL tools (V.1.13.1). Variables relevant to the risk of AKI were evaluated a priori, taking into consideration scientific literature, clinical significance, and predictors identified in prior studies (5, 17, 18).

For included patients, we collated data relating to clinical features as follows:

Demographic characteristics: sex, age, race.

Treatment modalities: use of diuretic use, use of aminoglycoside, use of human albumin therapy.

Comorbidities: chronic obstructive pulmonary disease (COPD), hypertension, hypotension, diabetes, heart failure, chronic liver disease, CKD, coronary and acute pancreatitis.

Laboratory test: hemoglobin, blood urea nitrogen (BUN), albumin (Alb), Serum creatinine (Scr), and glucose.

Outcome: AKI occurred during hospitalization.

For all laboratory test result parameters, we use the values at the time AKI occurred.

Missing data handling

In the MIMIC-IV database, a noteworthy prevalence of missing data is observed. However, the exclusion of patients with incomplete data may introduce significant bias into the study. To mitigate the impact of missing data, all variables used in the analyses were thoroughly evaluated. Less than 10% of missing values were identified across all variables. Consequently, imputation was conducted by replacing missing values with means for continuous variables with normal distributions and with medians for continuous variables with skewed distributions (19). Additionally, no dichotomous variables were missing from our study.

Definitions and outcomes

The primary outcome of interest during the ICU stay was AKI, which was defined according to the Kidney Disease Improving Global Outcomes (KDIGO) criteria (7). The use of diuretics, human albumin and aminoglycosides was categorized as any administration of these medications prior to the occurrence of AKI during the ICU stay for any indication. Hypotension was defined as any occurrence of systolic blood pressure less than 90 mmHg or diastolic blood pressure less than 60 mmHg before the onset of AKI.

Statistical analysis

Statistical analyses were conducted using SPSS version 26.0 (IBM, Armonk, NY, USA) and R version 4.2.1. Two-sided P-values were employed, with statistical significance defined as P < 0.05. Categorical variables were expressed as percentages, while continuous variables were reported as means \pm SD, medians, or ranges, depending on their normality of distribution. The chi-square test was utilized for categorical variables, while *t*-tests or Wilcoxon rank sum tests were employed for continuous variables, depending on their distributions.

To enhance the accuracy of forecasts and the comprehensibility of findings, the research employed least absolute shrinkage and selection operator (LASSO) regression analysis for variable selection and regularization (20). The variables identified in the LASSO regression model during the training phase were further examined using univariate logistic regression to determine their predictive significance for AKI (21). Variables demonstrating a *p*-value of less than 0.05 in the initial univariate logistic analyses were subsequently subjected to multivariable logistic regression analysis using a backward stepwise selection method. Additionally, the variance inflation factor (VIF) was calculated among the covariate variables in the multivariable logistic regression analysis, and VIF > 4.0 was interpreted as indicating multicollinearity. Variables with VIF > 4.0 weren't included in the final analysis. After constructing a predictive model through multivariable logistic regression analysis, a clinical prediction nomogram and an interactive web-based application were developed utilizing Shiny apps to estimate the likelihood of AKI.

The performance of the nomogram was evaluated in both the training and validation cohorts through assessments of

TABLE 1 Characteristics of patients in the training and validation cohorts.

Characteristic	Training Validation cohort cohort (n = 766) (n = 316)		<i>p</i> -value				
AKI, n (%)							
No	471 (61.5)	205 (64.9)	0.329				
Yes	295 (38.5)	111 (35.1)					
Race, <i>n</i> (%)							
White	500 (65.3)	208 (65.8)	0.829				
Black	77 (10.1)	28 (8.9)					
Other	189 (24.7)	80 (25.3)					
Sex, n (%)							
Female	291 (38.0)	108 (34.2)	0.266				
Male	475 (62.0)	208 (65.8)					
Age, years	61 (52, 73)	61 (52, 72)	0.864				
CKD, n (%)							
No	716 (93.5)	286 (90.5)	0.117				
Yes	50 (6.5)	30 (9.5)					
COPD, n (%)							
No	744 (97.1)	309 (97.8)	0.688				
Yes	22 (2.9)	7 (2.2)					
Coronary, n (%)							
No	709 (92.6)	298 (94.3)	0.370				
Yes	57 (7.4)	18 (5.7)					
Diabetes, n (%)							
No	681 (88.9)	277 (87.7)	0.631				
Yes	85 (11.1)	39 (12.3)					
Hypotension, n (%	5)						
No	734 (95.8)	304 (96.2)	0.906				
Yes	32 (4.2)	12 (3.8)					
Hypertension, n (%	%)						
No	586 (76.5)	247 (78.2)	0.609				
Yes	180 (23.5)	69 (21.8)					
Heart faire, n (%)							
No	698 (91.1)	289 (91.5)	0.954				
Yes	68 (8.9)	27 (8.5)					
Chronic liver disease, n (%)							
No	692 (90.3)	279 (88.3)	0.368				
Yes	74 (9.7)	37 (11.7)					
Use of human albumin, n (%)							
No	507 (66.2)	206 (65.2)	0.807				
Yes	259 (33.8)	110 (34.8)					
Acute pancreatitis, n (%)							
No	755 (98.6)	305 (96.5)	0.054				
Yes	11 (1.4)	11 (3.5)					

(Continued)

TABLE 1 (Continued)

Characteristic	Training cohort (n = 766)	Validation cohort (n = 316)	<i>p</i> -value				
Use of diuretic, n (%)							
No	612 (79.9)	242 (76.6)	0.257				
Yes	154 (20.1)	74 (23.4)					
Use of aminoglycosides, n (%)							
No	719 (93.9)	298 (94.3)	0.892				
Yes	47 (6.1)	18 (5.7)					
Hemoglobin, g/L	94 (84, 107)	94 (82, 105)	0.207				
Scr (umol/L)	80 (62, 133)	80 (62, 139)	0.814				
Blood urea nitrogen (mmol/L)	3.4 (2.2, 6.0)	3.7 (2.2, 6.0)	0.441				
Albumin (g/L)	30 (26, 35)	30 (26, 35)	0.979				
Glucose (mmol/L)	6.4 (5.3, 8.1)	6.2 (5.3, 7.9)	0.447				

Scr, Serum creatinine; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; AKI, actue kindey injure.

discrimination and calibration (22). Discrimination was measured using the C-index, which ranges from 0.5 (indicating no discrimination) to 1.0 (indicating perfect prediction), indicating the extent of predictive accuracy. Calibration was assessed by comparing predicted and actual probabilities of AKI occurrence through a visual calibration plot. Internal validation was conducted using 1000 bootstrap resamples to further evaluate the nomogram's predictive accuracy. Additionally, a decision curve analysis (DCA), which determines the net benefit of models and predictors, was performed to assess the clinical value of the nomogram (23).

Results

Characteristics of patients

A total of 1,082 patients presenting with acute NVUGIB were included in the study, with 406 patients (37.5%) testing positive for AKI. The average age of the patients was 62 years, with a majority (63.1%) being male. Patients were randomly divided into training (766 patients) and validation (316 patients) cohorts. Table 1 displays the demographic and clinical characteristics of patients in each cohort. Baseline clinical features were found to be comparable between the two cohorts, with AKI rates of 38.5% and 35.1% in the training and validation cohorts, respectively.

Nomogram variable screening

In this investigation, LASSO regression analysis was employed to identify 13 predictors with significant correlation to AKI from a pool of 21 potential predictors in the training cohort, as depicted in Figures 1A, B. The predictors associated with AKI as identified by the LASSO regression technique are detailed in Table 2 (lambda = 0.01038261). Following this, a multivariable logistic regression analysis was carried out to delve deeper into the variables that successfully passed through both univariate logistic regression and LASSO analyses.

Based on the findings of the stepwise logistic regression analysis, the model incorporating five independent predictors of AKI, including CKD, use of human albumin, chronic liver disease, glucose, and blood urea nitrogen, demonstrated the lowest AIC value within the training cohort. Additionally, the VIF values for all variables were less than 4, suggesting the absence of collinearity among the screened predictors (Table 2).

Nomogram construction and performance in the training cohort

Utilizing the outcomes of multivariate Logistic regression analysis, a nomogram (Figure 2A) was developed to visually represent a model incorporating independent predictors. For instance, a patient presenting with a blood urea nitrogen level of 14.3 mmol/L, glucose level of 12 mmol/L, absence of chronic liver disease and AKD, and using human albumin, possesses a current AKI risk score of 150, which equates to a 78% probability of developing AKI. This nomogram can be accessed online at https://risk-prediction-model-web-calculator20240327. shinyapps.io/AKI_probability_of_UBG/, as depicted in Figure 2B. Users are required to interact with the in-line graph by selecting either "Yes" or "No" from the provided options, inputting pertinent laboratory test results, and subsequently choosing "Predict" to ascertain the probability of AKI occurrence during the patient's ICU admission.

The C-index of the nomogram was calculated to be 0.73 (95% CI: 0.70–0.77) for the training cohort. The calibration curve illustrated in Figure 3A exhibits a satisfactory concordance between the anticipated and actual occurrences for the likelihood of AKI in the training cohort. The lack of statistical significance (P = 0.580) in the Hosmer–Lemeshow test implies that the model did not demonstrate overfitting.

External validation of the nomogram 2 in the validation cohort

In the validation cohort, the nomogram exhibited a C-index of 0.72 (95% CI 0.66–0.79) for the assessment of AKI risk. Additionally, a well-calibrated risk estimation was demonstrated through the calibration curve (Figure 3B).

Clinical value of the nomogram

Figure 4 illustrates the outcomes of decision curve analysis for the nomogram, highlighting the high-risk threshold probability at which a clinician can assess a patient's risk of AKI and the potential advantages of intervention. The decision curve indicates that employing the nomogram for AKI prediction can yield substantial benefits when a clinician's threshold probability falls between 7% and 54%, with the nomogram exhibiting greater predictive accuracy compared to a single predictor within this specified range.



FIGURE 1

LASSO Regression Analysis for Predictor Selection. (A) Tuning parameter (lambda) selection in the LASSO model using 10-fold cross-validation. The x-axis represents the log(lambda), and the y-axis represents the binomial deviance. The red dots indicate the average deviance values, and the vertical bars represent the standard errors. The vertical dashed lines represent the optimal values chosen by the minimum criteria and 1 standard error of the minimum criteria (the 1-SE rule). (B) LASSO coefficient profiles of the 21 potential predictors. Each curve represents a predictor, with the y-axis displaying the coefficient values and the x-axis representing the log(lambda). The numbers at the top of the plot indicate the number of predictors included in the model at each log(lambda) value.

Discussion

AKI is a serious complication in patients with acute NVUGIB significantly impacting morbidity and mortality. In this study, we developed a nomogram to quantitatively predict the risk of AKI in patients with acute non-variceal UGIB based on patientspecific factors. This predictive tool can be utilized to assess individual AKI risk, thereby facilitating personalized treatment and surveillance strategies. The significance of the present study lies in the development of the nomogram utilizing a substantial cohort of ICU patients diagnosed with acute non-variceal UGIB. Furthermore, the nomogram's performance underwent rigorous assessment and internal validation.

The current AKI diagnostic criteria, established by KDIGO in 2012, rely on changes in serum creatinine and urine output, which can miss early or subclinical AKI, depend on baseline creatinine levels that may not always be known, and are influenced by non-renal factors like hydration and muscle mass. Consequently, research efforts have been directed towards identifying susceptibility and exposure factors associated with AKI to facilitate preemptive preventive measures. These measures include optimizing fluid management, avoiding nephrotoxic medications, closely monitoring renal function in high-risk patients, and using alternative imaging methods to minimize contrast exposure. Nonetheless, the onset and progression of AKI involve intricate pathophysiological mechanisms, rendering the accurate assessment of AKI risk based on individual susceptibility and exposure challenging. This complexity often leads to the potential for over-treatment in preventive strategies. Another particular strength of this study is the consideration of a range of previously reported clinical features and laboratory findings related to AKI (5, 7, 17, 18, 24). In the present study, we similarly noted that CKD, glucose, chronic liver disease were closely related to AKI in patients with acute NVUGIB, which is consistent with most studies on variceal upper gastrointestinal bleeding (20-23). In contrast to variceal upper gastrointestinal bleeding, where albumin administration is generally advantageous for the prevention of AKI, our study identified a positive correlation between albumin use and the risk of AKI in patients with acute NVUGIB. This association may be attributable to enhanced albumin filtration and modified tubular albumin uptake in these individuals. Nonetheless, the relationship between human blood albumin administration and the incidence of AKI remains a subject of ongoing debate, (25-27), and the precise underlying mechanism remains uncertain. It is worth mentioning that we found that blood urea nitrogen was more predictive of AKI than Scr in patients with acute UGIB. This disparity may be attributable to fasting-induced alterations in muscle metabolism and renal blood flow, which influence Scr production and excretion. Despite these physiological changes, Scr levels tend to remain relatively stable and are less affected by shortterm dietary modifications. Conversely, blood urea nitrogen levels are more susceptible to variations in protein catabolism and renal perfusion, rendering blood urea nitrogen a more sensitive marker for detecting changes in renal function and assessing the risk of AKI in this patient population.

The capacity to precisely forecast the incidence of AKI in patients experiencing acute NVUGIB holds substantial importance, given that AKI represents a heterogeneous syndrome necessitating individualized care and management approaches (28). In contrast to the population-based or large cohort data utilized by KDIGO clinical practice guidelines, nomograms offer a more individualized approach to delivering prognostic information to patients. To the

TABLE 2	Univariate and	multivariate	loaistic	rearession	analyses of	f variables	relating to	AKI in the	training	cohort.

Variable	Univariat	e analysis	Multivariate analysis					
	OR (95% CI) p		OR (95% CI)	<i>p</i> -value				
Race								
White	Reference		Reference					
Black	1.03 (0.63, 1.70)	0.896	0.89 (0.51, 1.55)	0.680				
Other	1.61 (1.15, 2.26)	0.006	1.40 (0.96, 2.03)	0.080				
СКD								
No	Reference	<0.001	Reference	<0.001				
Yes	4.54 (2.40, 8.57)		3.62 (1.83, 7.15)					
Chronic liver disease								
No	Reference	<0.001	Reference	0.003				
Yes	2.92 (1.78, 4.79)		2.27 (1.33, 3.88)					
Use of human albumin								
No	Reference	<0.001	Reference	<0.001				
Yes	3.18 (2.33, 4.35)		2.45 (1.76, 3.42)					
Acute pancreatitis								
No	Reference	0.445	NA					
Yes	0.59 (0.16, 2.26)	-						
COPD								
No	Reference	0.019	Reference	0.080				
Yes	2.88 (1.19, 6.96)		2.39 (0.90, 6.31)					
Hypertension								
No	Reference	0.017	Reference	0.315				
Yes	1.51 (1.08, 2.12)		1.22 (0.83, 1.81)					
Diabetes								
No	Reference	0.002	Reference	0.221				
Yes	2.05 (1.30, 3.22)		1.40 (0.82, 2.41)					
Use of diuretic								
No	Reference	0.007	Reference	0.297				
Yes	1.64 (1.15, 2.34)		1.24 (0.83, 1.86)					
Hemoglobin	0.91 (0.76, 1.10)	0.348	NA					
Blood urea nitrogen	1.81 (1.51, 2.15)	<0.001	1.48 (1.23, 1.78)	<0.001				
Albumin	0.76 (0.63, 0.93)	0.006	0.86 (0.70, 1.07)	0.177				
Glucose	1.23 (1.08, 1.40)	0.002	1.21 (1.06, 1.39)	0.005				

best of our knowledge, this study represents the first attempt to develop an AKI risk prediction model that independently evaluates previously proposed risk variables for their inclusion in a formal nomogram specifically for patients with acute NVUGIB. Most studies on acute NVUGIB primarily concentrate on assessing the severity of bleeding, patient prognosis, and the risk of rebleeding. For instance, the Rockall score is employed to determine the necessity for further endoscopic intervention, while the Forrest score is utilized to evaluate the risk of endoscopic rebleeding (29). However, AKI, a complication associated with more severe short-term and long-term prognoses, is frequently overlooked. The lack of timely and effective interventions for AKI significantly exacerbates the complexity and cost of treatment. Therefore, we utilized clinically accessible laboratory results and assessed patients' susceptibility to AKI to develop a nomogram aimed at providing individualized AKI risk predictions for patients with acute NVUGIB in the intensive care unit. This approach aligns with the contemporary emphasis on personalized medicine.

The primary and ultimate justification for employing the nomogram lies in its capacity to assess the necessity for individualized supplementary treatment or care. Nevertheless, the metrics of risk-prediction performance, including discrimination and calibration, fail to encapsulate the clinical implications associated with specific levels of discrimination or degrees of miscalibration (30-32). Therefore, to substantiate the clinical utility



FIGURE 2

Nomogram for Predicting the Risk of AKI. (A) Nomogram to predict the risk of AKI in patients with acute NVUGIB. The nomogram integrates multiple predictors, including blood urea nitrogen (mmol/L), glucose (mmol/L), chronic liver disease, use of human albumin, and CKD. Each predictor has a corresponding point scale, which is used to calculate the total points. The total points are then used to determine the risk of AKI, displayed on the bottom scale. (B) Web-based calculator interface for predicting AKI risk. Users input values for blood urea nitrogen, glucose, chronic liver disease, use of human albumin, and CKD status to obtain the predicted probability of AKI. The example provided shows a current probability of AKI at 46.1%.



FIGURE 3

Calibration Curves for Nomogram Predicted Probability of AKI. These calibration plots compare the predicted probabilities of AKI against the actual observed probabilities, demonstrating the accuracy of the nomogram model. (A) Calibration curve for the training cohort. (B) Calibration curve for the validation cohort. The x-axis represents the nomogram predicted probability of AKI, while the y-axis shows the actual probability. The plot includes the apparent calibration (blue dotted line), the bias-corrected calibration (red solid line), and the ideal calibration (black dashed line). The closer the red line is to the black line, the more accurate the model.

of our nomogram, we undertook an evaluation to ascertain whether decisions informed by the nomogram would result in improved patient outcomes. Considering the inherent difficulties of executing a multi-institutional prospective validation, particularly due to the complexities involved in aggregating clinical data from multiple institutions, we opted to utilize decision curve analysis as an alternative methodological approach in this study. This study introduces an innovative methodology for evaluating the clinical



disease, glucose levels, and blood urea nitrogen.

implications of decisions grounded in threshold probability, thereby facilitating the calculation of net benefit (16, 33). The decision curve analysis conducted herein reveals that employing a nomogram for the prediction of AKI yields greater benefits when the threshold probability for physicians between 7% and 54%, as opposed to the strategies of treating all patients or treating none.

This study has limitations. First, its monocentric design within a single ICU, which restricts the generalizability of the findings and the dynamic online nomogram to other centers or countries. Further research is needed to validate the model in varied settings. Second, the MIMIC database's lack of novel biomarkers, such as cystatin C, neutral gelatin-associated lipocalcin, NTproBNP, uNGAL, and uAGT, precluded us from enhancing the model's predictive capacity. Third, the retrospective design of the study inherently limited our ability to eliminate bias. However, rigorous inclusion criteria were applied to ensure that both the control and case groups accurately reflected realworld conditions.

Conclusion

Our study presents an innovative online nomogram that incorporates clinical risk factors to facilitate personalized prediction of AKI in patients with acute NVUGIB upon ICU admission. This predictive tool holds significant potential in identifying acute NVUGIB patients who are most likely to benefit from targeted interventions for the prevention and management of AKI.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving humans were approved by the institutional review boards of the Beth Israel Deaconess Medical Center (Boston, MA) and Massachusetts Institute of Technology (Cambridge, MA). The studies were conducted in accordance with the local legislation and institutional requirements. The ethics committee/institutional review board waived the requirement of written informed consent for participation from the participants or the participants' legal guardians/next of kin because the study did not disclose any patient privacy.

Author contributions

CW: Writing – original draft, Software, Methodology, Investigation, Formal analysis. HC: Writing – original draft, Validation, Software, Resources, Methodology, Formal analysis, Data curation. LH: Writing – original draft, Validation, Software, Resources, Methodology, Formal analysis. L-HF: Writing – review and editing, Writing – original draft, Software, Methodology, Formal analysis.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of the article. This work was supported by grants from the Natural Science Foundation of Guangxi (NO. 2021GXNSFAA220036).

References

1. Benedeto-Stojanov D, Bjelaković M, Stojanov D, Aleksovski B. Prediction of in-hospital mortality after acute upper gastrointestinal bleeding: Cross-validation of several risk scoring systems. J Int Med Res. (2022) 50:3000605221086442. doi: 10.1177/ 03000605221086442

2. Hoste E, Bagshaw S, Bellomo R, Cely C, Colman R, Cruz D, et al. Epidemiology of acute kidney injury in critically ill patients: The multinational AKI-EPI study. *Intensive Care Med.* (2015) 41:1411–23. doi: 10.1007/s00134-015-3934-7

3. Kellum J, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders H. Acute kidney injury. *Nat Rev Dis Prim.* (2021) 7:52.

4. Ronco C, Bellomo R, Kellum J. Acute kidney injury. Lancet. (2019) 394:1949-64.

5. Cakmak U, Merhametsiz O, Gok Oguz E, Ercan Z, Haspulat A, Ozkan S, et al. Effects of acute kidney injury on clinical outcomes in patients with upper gastrointestinal bleeding. *Ren Fail.* (2016) 38:176–84.

6. Joannidis M, Druml W, Forni L, Groeneveld A, Honore P, Hoste E, et al. Prevention of acute kidney injury and protection of renal function in the intensive care unit: Update 2017: Expert opinion of the working group on prevention, AKI section, European society of intensive care medicine. *Intensive Care Med.* (2017) 43:730–49. doi: 10.1007/s00134-017-4832-y

7. Kellum J, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: A KDIGO summary (Part 1). Crit Care. (2013) 17:204. doi: 10.1186/cc11454

8. Grams M, Waikar S, MacMahon B, Whelton S, Ballew S, Coresh J. Performance and limitations of administrative data in the identification of AKI. *Clin J Am Soc Nephrol.* (2014) 9:682–9.

9. Bhatraju P, Wurfel M, Himmelfarb J. Trajectory of kidney function: The canary in sepsis. *Am J Respir Crit Care Med.* (2020) 202:1211–2. doi: 10.1164/rccm.202007-2627ED

10. Bonavia A, Singbartl K. Kidney injury and electrolyte abnormalities in liver failure. *Semin Respir Crit Care Med.* (2018) 39:556–65.

11. Angeli P, Gines P, Wong F, Bernardi M, Boyer T, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. *Gut.* (2015) 64:531–7.

12. Feng L, Bu K, Ren S, Yang Z, Li B, Deng C. Nomogram for predicting risk of digestive carcinoma among patients with type 2 diabetes. *Diabetes Metab Syndrome Obes Targets Ther.* (2020) 13:1763–70. doi: 10.2147/DMSO.S251063

13. Iasonos A, Schrag D, Raj G, Panageas K. How to build and interpret a nomogram for cancer prognosis. *J Clin Oncol.* (2008) 26:1364–70.

14. Hsieh Y, Lee K, Chen P, Su C, Hou M, Lin H. Acute kidney injury predicts mortality in cirrhotic patients with gastric variceal bleeding. *J Gastroenterol Hepatol.* (2017) 32:1859–66.

15. Feng L, Lu Y, Ren S, Liang H, Wei L, Jiang J. Development and validation of a dynamic online nomogram for predicting acute kidney injury in cirrhotic patients upon ICU admission. *Front Med (Lausanne).* (2023) 10:1055137. doi: 10.3389/fmed. 2023.1055137

16. Collins G, Reitsma J, Altman D, Moons K. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement. *BMJ*. (2015) 350: g7594.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

17. Wu P, Wu C, Lin C, Wu V. Long-term risk of upper gastrointestinal hemorrhage after advanced AKI. *Clin J Am Soc Nephrol.* (2015) 10:353–62.

18. Alkhatib A, Lam A, Shihab F, Adler D. RIFLE criteria accurately identifies renal dysfunction and renal failure in elderly patients with upper gastrointestinal hemorrhage: A pilot study. *South Med J.* (2009) 102:580–4. doi: 10.1097/SMJ. 0b013e3181a5cec9

19. Zhang Z. Missing data imputation: Focusing on single imputation. Ann Transl Med. (2016) 4:9.

20. Kaufman J. Acute kidney injury in CKD: Role of metabolic acidosis. *Kidney Int Rep.* (2022) 7:2555–7.

21. Yang L. How acute kidney injury contributes to renal fibrosis. *Adv Exp Med Biol.* (2019) 1165:117–42.

22. Lee H, Seo Y. Current knowledge about biomarkers of acute kidney injury in liver cirrhosis. *Clin Mol Hepatol.* (2022) 28:31-46.

23. Cullaro G, Verna E, Duarte-Rojo A, Kappus M, Ganger D, Rahimi R, et al. Frailty and the risk of acute kidney injury among patients with cirrhosis. *Hepatol Commun.* (2022) 6:910–9.

24. Gameiro J, Fonseca J, Outerelo C, Lopes J. Acute kidney injury: From diagnosis to prevention and treatment strategies. J Clin Med. (2020) 9:1704.

25. Frenette A, Bouchard J, Bernier P, Charbonneau A, Nguyen L, Rioux J, et al. Albumin administration is associated with acute kidney injury in cardiac surgery: A propensity score analysis. *Crit Care.* (2014) 18:602.

26. Lee E, Kim W, Kim J, Chin J, Choi D, Sim J, et al. Effect of exogenous albumin on the incidence of postoperative acute kidney injury in patients undergoing off-pump coronary artery bypass surgery with a preoperative albumin level of less than 4.0 g/dl. *Anesthesiology.* (2016) 124:1001–11. doi: 10.1097/ALN.00000000001051

27. James M, Grams M, Woodward M, Elley C, Green J, Wheeler D, et al. A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with acute kidney injury. *Am J Kidney Dis.* (2015) 66:602–12. doi: 10.1053/j.ajkd.2015.02.338

28. Arora T, Martin M, Grimshaw A, Mansour S, Wilson F. Prediction of outcomes after acute kidney injury in hospitalised patients: Protocol for a systematic review. *BMJ Open.* (2020) 10:e042035.

29. Yin L, Yu W. Retrospective analysis of risk factors for non-variceal upper gastrointestinal bleeding and construction of a nomogram prediction model. *Am J Transl Res.* (2023) 15:3385–93.

30. Sauerbrei W, Boulesteix A, Binder H. Stability investigations of multivariable regression models derived from low- and high-dimensional data. *J Biopharm Stat.* (2011) 21:1206–31. doi: 10.1080/10543406.2011.629890

31. Localio A, Goodman S. Beyond the usual prediction accuracy metrics: Reporting results for clinical decision making. *Ann Intern Med.* (2012) 157:294–5. doi: 10.7326/0003-4819-157-4-201208210-00014

32. Van Calster B, Vickers A. Calibration of risk prediction models: Impact on decision-analytic performance. *Med Decis Mak.* (2015) 35:162–9.

33. Balachandran V, Gonen M, Smith J, DeMatteo R. Nomograms in oncology: More than meets the eye. *Lancet Oncol.* (2015) 16:e173–80. doi: 10.1016/S1470-2045(14) 71116-7